1
BACKGROUND: Cytochrome P450 2D6 (CYP2D6), one of the most important drug-metabolizing enzymes, has been reported to possess variation in the encoding CYP2D6 gene (cytochrome P450, family 2, subfamily D, polypeptide 6) that affects enzymatic activity. For the pharmacogenetic study of CYP2D6, accurate measurement of the dosage of the functional gene is essential; however, current genotyping techniques are insufficient because of their inability to provide the exact copy number of functional CYP2D6 genes.
METHODS:
We developed 3 quantitative real-time PCR (qPCR) assays for estimating the total copy number of the CYP2D6 gene, as well as 24-multiplex PCR-based real-time Invader assays (mPCR-RETINAs) for estimating the allele ratio at each variation locus. After determining the allele copy number at each locus, we estimated the frequencies of CYP2D6 alleles in a population and the diplotype in each individual by a CNVphaser (copy number variation phaser). The qPCR assays and RETINAs used for HapMap Japanese and Chinese samples were applied to 455 Japanese individuals.
RESULTS: Forty-two individuals (9.2%) had one CYP2D6 gene copy, 207 (45.5%) had 2 copies, 161 (35.4%) had 3 copies, 40 (8.8%) had 4 copies, and 5 (1.1%) had 5 copies of the CYP2D6 gene. We found 16 different CYP2D6 alleles, with frequencies similar to those described in previous reports. In the diplotype analysis, we observed that CYP2D6*1/*1 and *1/*10-*36 were the most common diplotypes (approximately 20%) in our population.
CONCLUSIONS:
Our method is the first to determine the exact number of functional CYP2D6 gene copies. We believe our method will facilitate and accelerate the detailed pharmacogenetic analysis of CYP2D6.
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Cytochrome P450 2D6 (CYP2D6), 5 one of the key drug-metabolizing enzymes, is involved in the biotransformation of a large number of drugs, including ␤-blockers, antiarrhythmics, opioids, and a number of antidepressant and antipsychotic agents (1 ) . The CYP2D6 6 gene (cytochrome P450, family 2, subfamily D, polypeptide 6) is highly polymorphic, and Ͼ60 CYP2D6 alleles have been reported (http:// www.cypalleles.ki.se/). These CYP2D6 alleles consist of combinations of variants of single-nucleotide polymorphisms, short insertions and deletions, gene conversions, and copy number variants or variations (CNVs), including deletion and duplications/ multiplications of an entire gene. Approximately half of the reported CYP2D6 alleles affect enzymatic activity in vivo or in vitro, and some of them are closely related to treatment failure or to the toxicity of drugs metabolized by CYP2D6 (2) (3) (4) (5) (6) (7) .
We refer to the CYP2D6 alleles (haplotypes of variants) summarized in the human CYP allele database as "CYP2D6-alleles," whereas we use the term "allele" only for each locus of variation. For example, CYP2D6*10-*10 is defined as one CYP2D6-allele containing 2 copies of the CYP2D6 gene with 100CϾT alleles on one chromosome.
Several techniques have been reported for CYP2D6 genotyping, including the combination of long PCR and RFLP (8, 9 ) , AmpliChip CYP450 (Roche) (10, 11 ) , and SNaPshot (Applied Biosystems) (12 ) ; however, these methods detect only the presence or absence of each CYP2D6-allele or variant. Because of their inability to provide the exact copy number of functional CYP2D6 genes, these techniques are insufficient for estimating the functional effect of gene dosage on the efficacy or toxicity of drugs metabolized by CYP2D6 (13, 14 ) . In addition, these techniques require some improvements. Long PCR-RFLP, the gold standard for CYP2D6 genotyping, has been reported to have a high rate of amplification failure (Ͼ40%) (15 ) and to cause false-positive/falsenegative results in CNV detection because of unknown genomic alterations (16, 17 ) . Moreover, these techniques require multiple steps and long reaction times, leading to low throughputs.
Recently, we developed a multiplex PCR-based real-time Invader assay (mPCR-RETINA) that reveals the allele ratio at each locus within CNV regions by detecting allelic asymmetries (18 ) . By combining the allele ratio data with the data for total gene copy number obtained by real-time quantitative PCR (qPCR), we were able to measure the allele copy number at each locus (18 ) . We also developed CNVphaser software that can estimate both the haplotype frequency in a population and the diplotype of each individual within CNV regions (19 ) . We used these newly developed techniques to investigate how to determine the exact copy number of functional CYP2D6 genes in each individual.
Materials and Methods

GENOMIC DNA
We used 90 HapMap Japanese and Chinese (JCH) samples for assay development. We excluded 2 samples (NA18996 and NA18540) reported to have cell line artifacts (20 ) and used 88 samples for the evaluation. All JCH samples were purchased from Coriell Cell Repositories. We tested the assays in samples from 455 anonymous Japanese individuals provided by Biobank Japan (http://www.biobankjp.org), which collected genomic DNA after the patients had provided written informed consent to participate in this project. This study was approved by the institutional review board of the Ethical Committee at RIKEN.
MEASUREMENT OF TOTAL GENE COPY NUMBER BY qPCR
To determine the total copy number, we developed hydrolysis probe assays (5ЈFL, Int2, and Int6) at 3 different sites within or around the CYP2D6 gene (see Fig. 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/ content/vol55/issue8). Primers and probes were designed with the aid of Primer Express software v2.0 (Applied Biosystems) except for the reported assay of Int6 (21 ) . These hydrolysis probes were labeled with FAM at the 5Ј end and linked at the 3Ј end with a nonfluorescent quencher used in combination with a minor-groove binder moiety. Final concentrations of the primer and hydrolysis probe in 3 CYP2D6 assays were 900 nmol/L and 200 nmol/L, respectively. As the reference gene, we used the commercially available TaqMan Copy Number Reference Assay RNase P (Applied Biosystems). All assays were performed with TaqMan Universal PCR Master Mix (Applied Biosystems) according to the recommended protocol. The hydrolysis probe reaction was performed in a 1-tube biplex assay on an ABI Prism 7900 instrument (Applied Biosystems). We performed all qPCR experiments with a 384-well format in a 10-L reaction volume containing 10 ng genomic DNA. The qPCR thermal cycling conditions were as follows: initiation at 95°C for 10 min for hot start, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.
Copy number was calculated by the ⌬⌬Ct method, where Ct is the threshold cycle (18, (21) (22) (23) . The PCR efficiency of each assay was estimated from the calibration curves of a sample (NA18995) serially diluted from 40 ng to 2.5 ng of genomic DNA. PCR efficiency was calculated as 10 Ϫ1/slope Ϫ 1 (22, 23 ) . We examined the calibration curves 4 times and calculated the mean PCR efficiency in each assay. Mean PCR efficiencies of all assays ranged from 0.96 to 0.99 (5ЈFL and RNase P, 0.977 and 0.988, respectively; Int2 and RNase P, 0.982 and 0.964, respectively; Int6 and RNase P, 0.962 and 0.975, respectively; see Fig. 2 in the online Data Supplement), and they fulfilled the reported criteria (0.9 -1.1) for the ⌬⌬Ct method (23 ) .
All samples were examined in quadruplicate, and the mean, SD, SE, CV, and 95% CI for the mean were calculated for each sample. Mean CV values were 4.57% for 5ЈFL, 2.35% for Int2, and 3.44% for Int6 in JCH samples and were 3.65%, 3.53%, and 4.65%, respectively, in the 455 Japanese samples. We analyzed mean copy number values and 95% CIs for each sample in scatter plots. When the 95% CIs of the mean copy number value (mean Ϯ 1.96 ϫ SE) overlapped each other, we estimated that these samples had the same copy number. Table 1 in the online Data Supplement lists the primer and probe sequences for all of the assays.
MEASUREMENT OF ALLELE RATIO BY RETINA
RETINA monitors the fluorescence intensity of each allele in real time during the Invader assay and detects allelic asymmetries caused by genomic duplication/ multiplication in heterozygous individuals. Details for determining the allele ratio by RETINA have previously been described (18 ) . For the RETINA assay, we first amplified an entire CYP2D6 gene region via a triplex PCR with the previously reported primers (9, 15 ) . We used Takara Ex Taq HS (Takara Bio) according to the manufacturer's instructions at a primer concentra-tion of 250 nmol/L. Triplex PCR was performed on a GeneAmp 9700 PCR System (Applied Biosystems) in a 10-L reaction volume containing 10 ng of genomic DNA. The PCR conditions were as follows: initiation at 95°C for 2 min, 35 cycles of 98°C for 10 s and 68°C for 4 min, and termination at 68°C for 7 min. We designed Invader assays according to the guideline recommended by Third Wave Technologies except for the reported 6 loci (100CϾT, 883GϾC, 1707delT, 1846GϾA, 2549delA, and 2850CϾT) (15 ) . Fluorescence resonance energy transfer probes labeled with FAM or Yakima Yellow were purchased from Third Wave Technologies. ROX dye (6-carboxy-X-rhodamine; Sigma-Aldrich) was used to normalize reporter signals. We carried out 24 RETINA assays in duplicate in a 4-L reaction volume on an ABI Prism 7900 instrument with diluted triplex PCR products. The RETINA reaction conditions were 95°C for 5 min followed by 63°C for 10 min. The allele ratio at each locus was determined in each sample by analysis of allelic discrimination plots from calibration curves of the allele ratio (see Fig. 3 in the online Data Supplement) (18 ) .
CYP2D6 ALLELE ESTIMATION
We determined the allele copy number for each variant by combining the RETINA and qPCR results (18 ) . Allele copy number data were rounded to an integer (18 ) for haplotype/diplotype estimation of CYP2D6 alleles by the CNVphaser (19 ) . We adopted estimated haplotypes satisfying the haplotype-frequency threshold of 0.001 (Ͼ1/2n) (24 ) and also referenced known CYP2D6 alleles in the human CYP allele database. We defined CYP2D6*1 as such when the estimated haplotype had the wild type at all tested loci. In diplotype analysis, we extracted the diplotypes with the highest diplotype probability score in each individual.
DIRECT SEQUENCING, LONG PCR, AND SOUTHERN-RFLP
ANALYSIS
We performed direct sequencing to confirm the presence of variant alleles detected by RETINA with the ABI Prism 3700. Direct sequencing was performed with BigDye Terminator version 3.1 (Applied Biosystems) with the reported sequencing primers (25 ) . Sequence data were analyzed with SeqScape software (Applied Biosystems). We performed long PCR to confirm the estimated whole-gene deletion (CYP2D6*5) and duplications (CYP2D6*1-*1, *2-2, *10-*10, *10-*36, and *36-*36) according to the reported protocols (16, 26 ) . Furthermore, we performed Southern-RFLP analysis to confirm the new CYP2D6 alleles (*10-*36-*36 and *10-*10-*36) as previously described (27 ) by means of the AlkPhos Direct kit (GE Healthcare) for the Southern blot experiment.
Results
ASSAY DEVELOPMENT
We developed 3 qPCR assays with 88 JCH samples to determine the total copy number of the CYP2D6 gene. Fig. 1 presents the mean total copy number and the 95% CI for each sample. When we estimated the total copy number by the overlap in its 95% CI in the scatterplot analysis, our assays clearly estimated the total copy number for each sample at 1 to 4 copies. Among the 88 JCH samples, 6 individuals (6.8%) had 1 copy, 27 (30.7%) had 2 copies, 41 (46.6%) had 3 copies, and 14 (15.9%) had 4 copies of CYP2D6. The copy number values obtained for the 3 assays were concordant for all samples, indicating that the entire CYP2D6 gene had been duplicated or deleted as a unit. When we combined the results of 3 qPCR assays, we were able to obtain more precise copy number data (Fig. 1) .
Among the CYP2D6 alleles registered in the human CYP allele database, we selected 23 variants that have been reported to have functional significance for the CYP2D6 enzyme in vitro or in vivo (see Tables 2  and 3 in the online Data Supplement). We also selected 1 variant with wild-type function (2850CϾT) to determine the frequency of CYP2D6*2. With the 88 JCH samples, we performed RETINA assays for these 24 variants and found only 7 loci to be polymorphic in our population [100CϾT, 1707delT, 1758GϾA, 1846GϾA, 2573_2574insC, 2850CϾT, and gene conversion to CYP2D7P1 (cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 1) in exon 9 (Ex9_2D7conv)] (Fig. 2) . The other 17 RETINA assays detected no variant alleles in any of the JCH samples. The RETINA assays showed clear allelic asymmetries in the heterozygote clusters in the 100CϾT, 2850CϾT, and Ex9_2D7conv assays, and we observed variant alleles in 4 assays (1707delT, 1758GϾA, 1846GϾA, and 2573_2574insC) in 1 sample. The existence of all these variant alleles was confirmed by direct sequencing (see Fig. 4 in the online Data Supplement).
ESTIMATION OF CYP2D6 ALLELES IN 455 JAPANESE INDIVIDUALS
We subsequently performed qPCR assays and 24 RET-INA assays for 455 Japanese individuals. According to the results of 3 qPCR assays combined, we found that 42 individuals (9.2%) had 1 copy, 207 (45.5%) had 2 copies, 161 (35.4%) had 3 copies, 40 (8.8%) had 4 copies, and 5 (1.1%) had 5 copies of the CYP2D6 gene (see Fig. 5 in the online Data Supplement). The RETINA method indicated 7 loci to be polymorphic: 260 individuals (57.1%) had a 100CϾT allele, 3 (0.7%) had a 1758GϾA allele, 4 (0.9%) had a 1846GϾA allele, 5 (1.1%) had a 2573_2574insC allele, 122 (26.8%) had a 2850CϾT allele, 4 (0.9%) had a 4125_4133dupGTGC-CCACT allele, and 202 (44.4%) had an Ex9_2D7conv allele. A 1707delT allele found in 1 JCH sample was not observed in the 455 Japanese samples. These RETINA assays showed clear allelic asymmetries in the heterozygote clusters, and we determined the allele ratio of each variation in each individual. From the results obtained by qPCR and mPCR-RETINA, we determined the allele copy number at each variation locus and estimated the CYP2D6 allele with the CNVphaser. We found 16 different types of the CYP2D6 allele in the 455 Japanese individuals (Table 1) . CYP2D6*1, *2, and *10-*36 were the common CYP2D6 alleles, and CYP2D6*5 and *10 were relatively frequent (Ͼ5%). The frequencies of the other CYP2D6 alleles were very low. Although whole-gene deletion (CYP2D6*5) and duplications could previously be detected only by long PCR or the Southern-RFLP technique, our method was able detect these variations with the allele copy number data. In addition, we also detected novel CYP2D6 alleles, such as CYP2D6*10-*36-*36 and *10-*10-*36. When we compared the frequencies of CYP2D6 alleles with those described in previous reports (25, 26 ) , the results were very similar (Table 1 ). In the diplotype analysis, we found various CYP2D6 diplotypes (Table 2) . CYP2D6*1/*1 and *1/ *10-*36 were the most common diplotypes (approximately 20% each) in our population; other common diplotypes (Ͼ5%) were CYP2D6*1/*2, *2/*10-*36, *10-*36/*10-*36, *1/*5, and *1/*10.
CONFIRMATION OF ESTIMATED CYP2D6 ALLELES BY LONG PCR OR SOUTHERN-RFLP ANALYSIS
To confirm the estimated CYP2D6 alleles that composed the gene deletion, duplications, or triplications, we conducted long PCR or Southern-RFLP analysis according to previously described protocols (16, 26, 27 ) . Fig. 3 shows representative results of the confirmation by the long PCR method. We detected CYP2D6*5-specific PCR products (6 kb in lane 3, 3.5 kb in lane 4) in individuals estimated to have CYP2D6*5. The duplication-specific PCR products (4.8 kb for CYP2D6*1-*1, *2-*2, and *10-*10 in lane 5) were detected in individuals estimated to have these duplicated CYP2D6 alleles. We also observed CYP2D6*10-*36-or *36-*36-specific PCR products (6.4 kb in lane 5) in individuals estimated to have these CYP2D6 alleles. For the novel triplications (CYP2D6*10-*36-*36 and *10-*10-*36) found in this study, we performed Southern-RFLP analysis and detected a triplication-specific fragment (54 kb) in individuals estimated to have these CYP2D6 alleles (Fig. 4) .
Discussion
Accurate determination of the functional-gene dosage of CYP2D6 in pharmacogenetic studies is important, but presently available methods are inadequate to de- Scatter-plot analysis views of 3 qPCR assays for the total gene copy number determination. Closed purple, red, blue, and light green diamonds indicate 1 copy, 2 copies, 3 copies, and 4 copies, respectively. Error bars indicate the 95% CI.
termine it. To our knowledge, our method is the first to determine the exact copy number of nonfunctional, impaired-functional, and normal-functional CYP2D6 genes in each individual. Our genotyping method with a combination of qPCR and mPCR-RETINA was able to determine the allele copy number at each variation locus to precisely estimate the number of CYP2D6 alleles by the CNVphaser. Furthermore, our method could detect whole-gene deletion, duplications, and previously unreported CYP2D6 triplications without the use of the long PCR or Southern-RFLP technique. We think these characteristics are the crucial advantages of our method. We are confident that our method predicts CYP2D6 enzymatic activity more precisely and is useful for pharmacogenetic study of drugs metabolized by CYP2D6.
Although several genotyping methods have been developed for the detection of CYP2D6 alleles, they lack a quantitative capability and cannot provide an exact copy number of functional CYP2D6 genes. Duplication and multiplication of the CYP2D6 gene are usually considered as one CYP2D6 allele, such as CYP2D6*1xN, and the exact functional effect of gene dosage cannot be evaluated. In our population, 9.2% of the individuals had a loss of 1 copy of CYP2D6, 45.3% had more than 2 copies, and only less than half (45.5%) of our population had 2 copies of CYP2D6. Because different types of CYP2D6 variation are known to affect the function of CYP2D6 activity, accurate determination of the functional-gene dosage is essential for detailed pharmacogenetic analysis of CYP2D6. At a frequency of 34.8%, CYP2D6*10 is common in our population, but it is represented by various , and 2 individuals had 3 copies of CYP2D6*10 (*10-*36/*10-*10-*36). Because differences in CYP2D6*10 copy number are thought to affect differences in enzymatic activity (3, 28 ) , the risk of treatment failure or toxicity of drugs metabolized by CYP2D6 might be different among these individuals. We believe our method will contribute to establishing a more detailed and precise estimation of CYP2D6 enzymatic activity. In addition to the advantage of quantitative capability, our method has other merits. The most critical point is the ease of the protocol with its highthroughput format. Long PCR-RFLP requires 4 steps, including long PCR, nested PCR, cleavage by restriction enzymes, and gel electrophoresis (8 ) . The AmpliChip CYP450 method requires 5 steps, including long PCR, fragmentation, labeling, hybridization, and staining (11 ) , and the SNaPshot method requires 5 steps (long PCR, purification of the PCR product, primer extension, removal of unincorporated dideoxynucleoside triphosphates, and electrophoresis on a genetic analyzer) (12 ) . All of these methods require approximately 1-2 days or longer to obtain the final results. In contrast, qPCR is a 1-step reaction as a homogeneous assay, and mPCR-RETINA is just a 2-step reaction of PCR combined with the Invader assay. Both can be performed in a 384-well plate format. The qPCR requires 2 h, the triplex PCR requires 3 h, and RETINA requires only 15 min. Because the qPCR and mPCR-RETINA assays can be run on different platforms simultaneously, we can obtain allele copy number data within several hours. Our method has the advantages of labor efficiency and throughput. We believe our method will be a powerful tool for the pharmacogenetic study of CYP2D6. 
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